Clinical Trial

ctDNA Monitoring in Early Breast Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 18, 2024 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a observational, single center study, monitoring the circulating tumor DNA (ctDNA) in patients with early breast cancer and assessing the prognostic value and treatment outcome monitoring of ctDNA.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-04-16; most recent amendment 2024-07-16.
Trial Details
NCT Number NCT04353557
Lead Sponsor Geneplus-Beijing Co. Ltd.
Collaborators: Army Medical University, China
Conditions Breast Cancer
Enrollment 200 participants
Start Date 2019-11-29
Primary Completion 2025-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-07-18